The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crank, J. (1956) · CERN Document Server (European Organization for Nuclear Research) · Cited by 18,978
Park, G. S. (1975) · Polymer · doi:10.1016/0032-3861(75)90130-5 · Cited by 14,967
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Improved tumor perfusion and convective flow may also be achieved by vascular ‘normalization’ with anti-angiogenic drugs [149,150].”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Cited by
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Van Straten, D., Mashayekhi, V., De Bruijn, H., Oliveira, S., & Robinson, D. (2017) · Cancers · doi:10.3390/cancers9020019 · Cited by 1,012
Targeting of drugs and nanoparticles to tumors
Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
Advances in the formation, use and understanding of multi-cellular spheroids
Achilli, T.-M., Meyer, J., & Morgan, J. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707181 · Cited by 572
Liu, J. K. H. (2014) · Annals of Medicine & Surgery · doi:10.1016/j.amsu.2014.09.001 · Cited by 515
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
Lee, H., Fonge, H., Hoang, B., Reilly, R. M., & Allen, C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100038h · Cited by 349
Antibody–Drug Conjugates for Cancer Treatment
Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 314
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A., Wessels, H. J., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 277
Viral nanoparticles as platforms for next-generation therapeutics and imaging devices
Steinmetz, N. F. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.04.005 · Cited by 259
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Maruani, A., Smith, M. E. B., Miranda, E., Chester, K. A., Chudasama, V., & Caddick, S. (2015) · Nature Communications · doi:10.1038/ncomms7645 · Cited by 256
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Liu, K., Li, M., Li, Y., Li, Y., Chen, Z., Tang, Y., Yang, M., Deng, G., & Liu, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01963-7 · Cited by 196
Role of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178
Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles
Souri, M., Soltani, M., Moradi Kashkooli, F., & Kiani Shahvandi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.024 · Cited by 178
Nessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., Abu-Yousif, A. O., Sandal, T., Legg, J., Thompson, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2295 · Cited by 128
Self-citationDeng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Zhang, Z.-T., Huang-Fu, M.-Y., Xu, W.-H., & Han, M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.02.009 · Cited by 82
Assessing the benefits of drug delivery by nanocarriers: a partico/pharmacokinetic framework
Siegel, R. A., Kirtane, A. R., & Panyam, J. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2632733 · Cited by 14
Metadata
- Authors
- Thurber, G. M., Schmidt, M. M., & Wittrup, K. D.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 60
- Issue
- 12
- Pages
- 1421-1434
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2037248548
- Cited by
- 624
- References
- 134
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.